Johnson & Johnson’s novel blood thinning drug Xarelto has been on a meteoric rise since its introduction in 2011. In recent years, it has racked up additional FDA approvals and eclipsed both competitors Eliquis and Pradaxa in sales.
The doctor leading the charge against the use of power morcellator devices for hysterectomies and myomectomies says the FDA is likely to add restrictions, but will not ban their use.
Dr. Hooman Noorchashm, a cardiac surgeon, began a full-time effort last fall to bring the dangers of the surgical devices to light after his wife, anesthesiologist Dr. Amy Reed, developed accelerated uterine cancer following a laparoscopic fibroid removal.
Most people recognize prescription drugs only by the brand names they see in advertisements each day. However, did you know that approximately 75% of the medications taken in the United States every year are generic?
And, with increasing pressure by insurance companies and changing healthcare laws, more and more people could be forced to switch from brand name meds to cheaper generics.
A growing number of patients who’ve filed lawsuits against Bayer and Johnson & Johnson alleging their popular blood thinner Xarelto caused uncontrollable internal bleeding will soon know how and where their cases will be handled.
Last week, the Judicial Panel on Multidistrict Litigation, or JPML, issued their latest hearing order indicating the panel will hear arguments over Xarelto product liability claims at their next session on December 4th in Charleston, South Carolina.
This month, Senator Robert Casey Jr. from Pennsylvania became the latest member of Congress to draft a letter to the FDA expressing concern about the continued use of power morcellators for hysterectomies and fibroid removal surgeries.
The oversight is a welcome sign after a year in which the machines have been linked to spreading deadly uterine cancer in numerous patients. However, Senator Casey is only the third member to take the initiative to protect the public in this way.
The European Medicines Agency, or EMA, came out this week in support of testosterone replacement therapy (TRT) drugs, but recommended they only be used in limited circumstances by those who actually need them.
The agency indicated the benefits of TRT drugs still outweigh the risks, but stated patients should be tested for hypogonadism, or low testosterone levels, before they are prescribed.
A new study from the University of Illinois in Chicago has established a link between popular testosterone replacement therapy (TRT) drugs and prostate cancer.
And, although additional testing is needed on humans, these early indications are troubling with the increasing use of these medications by millions of men each year.
Contraceptive methods are a uniquely personal choice for women. After testing different brands for compatibility and side effects, most become fiercely loyal to their favorite.
Although the use of patches, rings, IUDs and injections is on the rise in the past decade, the traditional birth control pill is still the most common form of prescription birth control. However, these come with risks.
California pharmaceutical pioneer Portola Pharmaceuticals announced recently that they have completed the second round of clinical trials for an antidote that could stop bleeding in emergencies for millions of people taking new generation blood thinners.
This is the latest step in a long process towards FDA approval; however, records show thousands of users could benefit immediately.
This month, the Judicial Panel on Multidistrict Litigation released their latest report showing 7,606 Yaz lawsuits are still pending in a federal multidistrict court in the Southern District of Illinois.
The cases had numbered above 10,000 in recent years, until Bayer, who makes Yaz and Yasmin, began a massive settlement program for those suffering blood clot injuries.
Just as Cymbalta victims are getting closer to having their day in court over serious withdrawal side effects, the maker of the drug is trying to block their lawsuits.
Last week, Eli Lilly filed a motion to dismiss a New York Cymbalta lawsuit filed by a man that suffered severe electrical brain zaps when he tried to stop using the drug. The company claimed the label has always warned of such side effects since it was introduced in 2004.
For years, Bayer has been paying settlements to women who were hospitalized for blood clots, DVT and pulmonary embolism while taking the birth control drugs Yaz or Yasmin.
In fact, recent company records show they have now paid out over $1.8 billion to almost 9,000 victims over Yaz blood clots, at an average of more than $200,000 per case. By doing so, Bayer avoided litigation and public attention in thousands of cases.